Supplementary Figure 23. Subgroup analysis of Composite Outcome for COVID-19 with Incidence in Control from 40% to 80

Subgroup	Glucocorticoids (No. events/total)	Control (No. events/total)	RR	95% CI	Weight %	Favours glucocorticoids / Favours control	Incidence of events in control	Design type of included studies	Risk of bias of included studies
Age									
Elder(I²=NA%, p=NA)	15/27	6/9	0.83	[0.47; 1.47]	59.4		0.67	RCTs	Non−high
Young(I²=NA%, p=NA)	1/22	10/20	0.09	[0.01; 0.73]	40.6		0.5	RCTs	Non−high
Doses of glucocorticoids									
Low dose(I²=0%, p=.96)	58/132	53/102	0.83	[0.64; 1.08]	NA		0.52	RCTs	Non−high
Low dose(I²=0%, p=.91)	82/358	203/453	0.51	[0.46; 0.56]	NA		0.45	Observational	Low/Some concerns/High
Low dose(I²=NA%, p=NA)	19/83	40/90	0.41	[0.24; 0.71]	NA		0.44	Observational	Low
Severity of illness									
Critically severe(I²=NA%, p=NA)	32/76	37/73	0.83	[0.59; 1.17]	NA		0.51	RCTs	Non−high
Types of glucocorticoids									
Hydrocortisone(I²=NA%, p=NA)	32/76	37/73	0.83	[0.59; 1.17]	60.7		0.51	RCTs	Non−high
Methylprednisolone(I²=NA%, p=NA)	26/56	16/29	0.84	[0.55; 1.29]	39.3		0.55	RCTs	Non−high
Methylprednisolone(I²=0%, p=.80)	76/332	160/360	0.51	[0.46; 0.56]	NA		0.44	Observational	Low/Some concerns/High
Methylprednisolone(I²=NA%, p=NA)	19/83	40/90	0.41	[0.24; 0.71]	NA		0.44	Observational	Low

Risk Ratio (95% CI)
0.1 0.2 0.5 1 2 5 10